Form 4: AGIOS CMO Exercises Options, Sells Shares
Insider Transaction Report
Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, exercised stock options and subsequently sold a portion of the acquired common stock under a Rule 10b5-1 trading plan.
Summary
- Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, Inc., engaged in transactions involving company stock.
- On November 11, 2025, Gheuens exercised stock options to acquire 2,454 shares of common stock at an exercise price of $25.01 per share.
- Immediately following the exercise, Gheuens sold all 2,454 shares of common stock at a weighted average price of $43.78 per share.
- The sale was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
- Following these transactions, Gheuens beneficially owns 61,727 shares of common stock directly.
- Gheuens also holds 26,130 stock options (right to buy) with an exercise price of $25.01, which were originally granted on March 1, 2023, and vest over time.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction where the Chief Medical Officer exercised stock options and immediately sold the acquired shares under a pre-arranged 10b5-1 trading plan. This is a common practice for executive compensation and liquidity, making the sentiment neutral, though some investors may view insider selling as a minor negative.
Positives
- The exercise of options indicates a profit for the insider, as the sale price ($43.78) was significantly higher than the exercise price ($25.01).
- The transaction was conducted under a Rule 10b5-1 trading plan, which suggests pre-planning and reduces concerns about opportunistic insider trading.
Negatives
- An insider selling shares, even under a 10b5-1 plan, could be interpreted by some investors as a lack of conviction in the company's near-term stock price appreciation.
- The sale reduced the direct beneficial ownership of common stock by the Chief Medical Officer.
Risks
- NA
Future Outlook
NA
Industry Context
NA
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- Sarah Gheuens, Chief Medical Officer, exercised stock options and sold common stock of Agios Pharmaceuticals, Inc. This is a standard related-party transaction for executive compensation and liquidity.
Stakeholder Impact
- Shareholders: May interpret the insider sale differently; some may see it as a routine liquidity event, others as a slight negative signal regarding management's near-term outlook for the stock.
- Employees: No direct impact on employees is indicated by this transaction.
- Customers: No direct impact on customers is indicated by this transaction.
- Suppliers: No direct impact on suppliers is indicated by this transaction.
- Creditors: No direct impact on creditors is indicated by this transaction.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 03/01/2023 | Original grant date of the stock option for 44,000 shares. |
| 03/01/2024 | First vesting date for 25% of the underlying option shares. |
| 11/11/2025 | Date of option exercise and subsequent sale of common stock by Sarah Gheuens. |
| 11/13/2025 | Signature date of the reporting person's attorney-in-fact. |
| 03/01/2033 | Expiration date of the stock option. |
Keywords
AGIOS PHARMACEUTICALS, AGIO, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Chief Medical Officer, Sarah Gheuens, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.